Aldeyra Therapeutics (NASDAQ:ALDX) Given News Sentiment Rating of 0.07

News articles about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aldeyra Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.3845283663726 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Aldeyra Therapeutics (ALDX) traded up $0.15 on Thursday, reaching $6.90. The company’s stock had a trading volume of 148,735 shares, compared to its average volume of 87,987. Aldeyra Therapeutics has a 52-week low of $3.80 and a 52-week high of $11.90. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.35 and a quick ratio of 20.35. The company has a market cap of $131.91, a price-to-earnings ratio of -4.89 and a beta of 0.53.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.09. equities analysts forecast that Aldeyra Therapeutics will post -1.39 earnings per share for the current fiscal year.

ALDX has been the subject of several recent analyst reports. Zacks Investment Research upgraded Aldeyra Therapeutics from a “sell” rating to a “buy” rating and set a $6.75 target price for the company in a research note on Tuesday, November 14th. Canaccord Genuity reaffirmed a “buy” rating and issued a $27.00 price target (up previously from $12.00) on shares of Aldeyra Therapeutics in a report on Wednesday, September 13th. Cowen reaffirmed an “outperform” rating and issued a $14.00 price target (up previously from $9.00) on shares of Aldeyra Therapeutics in a report on Thursday, September 14th. Cantor Fitzgerald started coverage on Aldeyra Therapeutics in a report on Tuesday, October 24th. They issued an “overweight” rating and a $22.00 target price for the company. Finally, ValuEngine cut Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $17.42.

ILLEGAL ACTIVITY NOTICE: This report was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Insider Buying and Selling by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply